Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET/MRI for Focal Therapy Selection in Prostate Cancer
NCT07747493Not yet recruiting
- Sponsor
- University Health Network
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University Health Network. Primary endpoint: Specificity of 68Ga-PSMA-11 PET/MRI for Determining Eligibility for Focal Therapy at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07747493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747493.